MeSH D055953 - microscopic polyangiitis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Amgen | Rituximab | Riabni |  | 2020-12-17 |  |  |
| Biogen | Rituximab | Rituxan |  | 2002-02-19 |  |  |
| Celltrion | Rituximab | Blitzima |  | 2017-07-13 |  |  |
| Rituximab | Ritemvia |  | 2017-07-13 |  |  | |
| Rituximab | Rituzena (previously Tuxella) |  | 2017-07-13 |  |  | |
| Rituximab | Truxima |  | 2018-11-28 |  |  | |
| Genentech | Rituximab | Rituxan |  | 1997-11-26 |  |  |
| Rituximab, Hyaluronidase (human recombinant) | Rituxan Hycela |  | 2017-06-22 |  |  | |
| Pfizer | Rituximab | Ruxience |  | 2019-07-23 | $390 M | Y2023 |
| Roche | Rituximab | MabThera |  | 1998-06-02 |  |  |
| Sandoz | Rituximab | Rixathon |  | 2017-06-15 |  |  |
| Rituximab | Riximyo |  | 2017-06-15 |  |  |
Clinical Trials
Historical Success Rate
Phase 1
100%2/2
Phase 2
87%13/15
Phase 3
93%13/14
Approved: 3Overall Success rate: 80%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use